These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 26367217)

  • 1. A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT.
    Bensinger WI; Becker PS; Gooley TA; Chauncey TR; Maloney DG; Gopal AK; Green DJ; Press OW; Lill M; Ifthikharuddin JJ; Vescio R; Holmberg LA; Phillips GL
    Bone Marrow Transplant; 2016 Jan; 51(1):67-71. PubMed ID: 26367217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
    Blanes M; Lahuerta JJ; González JD; Ribas P; Solano C; Alegre A; Bladé J; San Miguel JF; Sanz MA; de la Rubia J
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):69-74. PubMed ID: 22897964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma.
    Lahuerta JJ; Grande C; Blade J; Martínez-López J; de la Serna J; Alegre A; Garcia LJ; Caballero D; de la Rubia J; Marín J; Perez-Lopez C; Sureda A; Escudero A; Cabrera R; Conde E; García-Ruiz JC; Pérez-Equiza K; Hernandez F; Palomera L; León A; Giraldo P; Solano C; Bargay J; San MJ;
    Leuk Lymphoma; 2002 Jan; 43(1):67-74. PubMed ID: 11908738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma.
    Barta SK; Jain R; Mazumder A; Carter J; Almanzar L; Browne R; Shahnaz S; Elkind R; Kaminetzky D; Battini R; Derman O; Kornblum N; Verma A; Braunschweig I
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):650-657. PubMed ID: 28684379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.
    Palumbo A; Bringhen S; Bruno B; Falcone AP; Liberati AM; Grasso M; Ria R; Pisani F; Cangialosi C; Caravita T; Levi A; Meloni G; Nozza A; Pregno P; Gabbas A; Callea V; Rizzo M; Annino L; De Stefano V; Musto P; Baldi I; Cavallo F; Petrucci MT; Massaia M; Boccadoro M
    Blood; 2010 Mar; 115(10):1873-9. PubMed ID: 19965659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study.
    Ghilardi G; Pabst T; Jeker B; Müller R; Cairoli A; Müller AMS; Bargetzi M; Hitz F; Baldomero H; Heim D; Schmidt A; Rossi D; Ghielmini M; Wannesson L; Lerch E; Samaras P; Schanz U; Passweg JR; Stussi G; Kleber M; Gerber B;
    Bone Marrow Transplant; 2019 Jul; 54(7):1029-1037. PubMed ID: 30390061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final outcomes of escalated melphalan 280 mg/m
    Hari P; Reece DE; Randhawa J; Flomenberg N; Howard DS; Badros AZ; Rapoport AP; Meisenberg BR; Filicko-Ohara J; Phillips GL; Vesole DH
    Bone Marrow Transplant; 2019 Feb; 54(2):293-299. PubMed ID: 29907806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.
    Katragadda L; McCullough LM; Dai Y; Hsu J; Byrne M; Hiemenz J; May S; Cogle CR; Norkin M; Brown RA; Wingard JR; Chang M; Moreb JS
    Clin Transplant; 2016 Aug; 30(8):894-900. PubMed ID: 27219740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma.
    Singh Abbi KK; Zheng J; Devlin SM; Giralt S; Landau H
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):468-72. PubMed ID: 25529381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m
    Patel P; Oh AL; Koshy M; Sweiss K; Saraf SL; Quigley JG; Khan I; Mahmud N; Hacker E; Ozer H; Peace DJ; Weichselbaum RR; Aydogan B; Rondelli D
    Leuk Lymphoma; 2018 Jul; 59(7):1666-1671. PubMed ID: 29065747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.
    Spencer A; Horvath N; Gibson J; Prince HM; Herrmann R; Bashford J; Joske D; Grigg A; McKendrick J; Prosser I; Lowenthal R; Deveridge S; Taylor K;
    Bone Marrow Transplant; 2005 May; 35(10):971-7. PubMed ID: 15778725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
    Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melphalan 200 mg/m
    Brioli A; Vom Hofe F; Rucci P; Ernst T; Yomade O; Hilgendorf I; Scholl S; Sayer H; Mügge LO; Hochhaus A; von Lilienfeld-Toal M
    Bone Marrow Transplant; 2021 May; 56(5):1209-1212. PubMed ID: 33299059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.
    Nair AP; Walker P; Kalff A; Bergin K; Hocking J; Avery S; Curtis DJ; Patil S; Das T; Klarica D; Morgan S; Muirhead J; Gorniak M; Reynolds J; Spencer A
    Bone Marrow Transplant; 2017 Jun; 52(6):839-845. PubMed ID: 28319080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.
    Marini C; Maia T; Bergantim R; Pires J; Aguiar E; Guimarães JE; Trigo F
    Ann Hematol; 2019 Feb; 98(2):369-379. PubMed ID: 30368589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing Outcomes in Patients With Multiple Myeloma Postautologous Stem Cell Transplantation: Contrasting the Effects of Melphalan Dosages at 200 mg/m
    Brown Z; Scott C; Zhang LF; Sadek R; Clarke A; Jillella A; Keruakous AR; Clemmons AB
    Clin Lymphoma Myeloma Leuk; 2024 Sep; 24(9):642-647. PubMed ID: 38845275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous transplantation and maintenance therapy in multiple myeloma.
    Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
    N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial.
    Blanes M; de la Rubia J; Lahuerta JJ; González JD; Ribas P; Solano C; Alegre A; Sanz MA
    Leuk Lymphoma; 2009 Feb; 50(2):216-22. PubMed ID: 19197734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.